Table 3.

Persistence of positivity to anti-N and anti-S antibodies and according to clinical classification of participant (n/N (%))

	Oligo/asymptomatic*	Symptomatic†	Hospital admitted	Total
Anti-spike serology
First follow-up  N=149	5/9 (55.6)	44/47 (93.6)	6/6 (100.0)	55/62 (88.7)
Second follow-up  N=128	8/11 (72.7)	59/65 (90.8)	18/18 (100.0)	85/94 (90.4)
Last follow-up  N=130	8/11 (72.7)	68/78 (87.2)	21/21 (100.0)	97/110 (88.2)
Antinucleocapside serology
First follow-up  N=149	10/17 (58.8)	78/107 (72.9)	23/25 (92.0)	111/149 (74.5)
Second follow-up  N=128	5/11 (45.5)	39/81 (48.2)	17/21 (81.0)	61/113 (54.0)
Last follow-up  N=130	1/11 (9.1)	22/80 (27.5)	10/22 (45.5)	33/113 (29.2)

Numbers in denominators are participants available at follow-up.

*Oligosymptomatic patients are those with symptoms enduring for less than 3 days or with only one symptom (anosmia/ageusia or asthenia).

†Symptomatic patients are those with one more symptom lasting at least 3 days and without any hospital admission.